Elicio Therapeutics, Inc. — All Filings
354 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-K/A
10-Q
3
3/A
4
4/A
424B3
424B4
424B5
425
8-A12B
8-A12B/A
8-K
8-K/A
ARS
CERT
CORRESP
D
DEF 14A
DEFA14A
DRS
DRS/A
DRSLTR
EFFECT
PRE 14A
RW
S-1
S-1/A
S-3
S-3/A
S-4
S-4/A
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| EFFECT | — | 9999999995-26-000830 | Mar 16, 2026 | — |
| 8-K | 8-K | 0001601485-26-000032 | Mar 16, 2026 | — |
| 424B5 | 424B5 | 0001628280-26-017941 | Mar 16, 2026 | — |
| S-8 | S-8 | 0001601485-26-000030 | Mar 12, 2026 | — |
| S-3/A | S-3/A | 0001628280-26-017302 | Mar 12, 2026 | — |
| 10-K | 10-K | 0001601485-26-000027 | Mar 12, 2026 | Dec 31, 2025 |
| 8-K | 8-K | 0001601485-26-000026 | Mar 12, 2026 | — |
| S-3/A | S-3/A | 0001628280-26-013187 | Mar 2, 2026 | — |
| S-3 | S-3 | 0001628280-26-012826 | Feb 27, 2026 | — |
| 4 | FORM 4 | 0001601485-26-000010 | Feb 3, 2026 | Feb 2, 2026 |
| 4 | FORM 4 | 0001601485-26-000008 | Feb 3, 2026 | Feb 2, 2026 |
| 4 | FORM 4 | 0001601485-26-000006 | Feb 3, 2026 | Feb 2, 2026 |
| 4 | FORM 4 | 0001601485-26-000002 | Feb 3, 2026 | Feb 2, 2026 |
| 4 | FORM 4 | 0001601485-25-000130 | Dec 10, 2025 | Dec 9, 2025 |
| EFFECT | — | 9999999995-25-003510 | Dec 3, 2025 | — |
| S-3 | S-3 | 0001628280-25-052119 | Nov 13, 2025 | — |
| 10-Q | 10-Q | 0001601485-25-000124 | Nov 13, 2025 | Sep 30, 2025 |
| 8-K | 8-K | 0001601485-25-000123 | Nov 13, 2025 | — |
| SCHEDULE 13G/A | — | 0002050492-25-000003 | Oct 7, 2025 | — |
| 8-K | 8-K | 0001193125-25-205522 | Sep 17, 2025 | — |
| 8-K | 8-K | 0001601485-25-000114 | Aug 12, 2025 | — |
| 10-Q | 10-Q | 0001601485-25-000111 | Aug 7, 2025 | Jun 30, 2025 |
| 8-K | 8-K | 0001601485-25-000108 | Aug 7, 2025 | — |
| 8-K | 8-K | 0001601485-25-000099 | Aug 5, 2025 | — |
| 4 | 4 | 0000950170-25-081741 | Jun 4, 2025 | Jun 3, 2025 |
| SCHEDULE 13D/A | — | 0000950170-25-081739 | Jun 4, 2025 | — |
| 8-K | 8-K | 0001601485-25-000096 | Jun 4, 2025 | — |
| 4 | FORM 4 | 0001601485-25-000090 | May 20, 2025 | May 19, 2025 |
| 4 | FORM 4 | 0001601485-25-000089 | May 20, 2025 | May 19, 2025 |
| 4 | FORM 4 | 0001601485-25-000088 | May 20, 2025 | May 19, 2025 |
| 4 | FORM 4 | 0001601485-25-000087 | May 20, 2025 | May 19, 2025 |
| 4 | FORM 4 | 0001601485-25-000086 | May 20, 2025 | May 19, 2025 |
| 4 | FORM 4 | 0001601485-25-000085 | May 20, 2025 | May 19, 2025 |
| 4 | FORM 4 | 0001601485-25-000084 | May 20, 2025 | May 19, 2025 |
| 8-K | 8-K | 0001601485-25-000076 | May 20, 2025 | May 19, 2025 |
| SCHEDULE 13G/A | — | 0002050492-25-000001 | May 14, 2025 | — |
| 10-Q | 10-Q | 0001601485-25-000074 | May 13, 2025 | Mar 31, 2025 |
| 8-K | 8-K | 0001601485-25-000072 | May 13, 2025 | — |
| 4 | FORM 4 | 0001601485-25-000065 | Apr 16, 2025 | Apr 15, 2025 |
| ARS | ARS | 0001601485-25-000063 | Apr 9, 2025 | Dec 31, 2024 |
| DEF 14A | DEF 14A | 0001601485-25-000062 | Apr 9, 2025 | — |
| 3 | FORM 3 | 0001601485-25-000053 | Apr 2, 2025 | Mar 24, 2025 |
| S-8 | S-8 | 0001601485-25-000051 | Mar 31, 2025 | — |
| 10-K | 10-K | 0001601485-25-000049 | Mar 31, 2025 | Dec 31, 2024 |
| 8-K | 8-K | 0001601485-25-000046 | Mar 31, 2025 | — |
| 8-K | 8-K | 0001601485-25-000022 | Mar 24, 2025 | Mar 21, 2025 |
| SCHEDULE 13D/A | — | 0000950170-25-035497 | Mar 7, 2025 | — |
| 4 | 4 | 0000950170-25-035494 | Mar 7, 2025 | Mar 5, 2025 |
| 8-K | 8-K | 0001601485-25-000018 | Mar 5, 2025 | — |
| SCHEDULE 13G | — | 0001104659-25-009441 | Feb 5, 2025 | — |